Omega-3 Supplementation on Serum Fetuin-A Levels
Condition: Coronary Artery Disease
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
Study type: Interventional

Summary: 
      Background and aims: One of the investigated possible modulators of serum fetuin-A,
      associated with the risk of developing coronary artery disease (CAD), is omega-3 fatty acids
      (FAs). This study aims to evaluate the effects of omega-3 FA supplementation on serum
      fetuin-A concentration in patients with CAD.

      Methods: The study was carried out on 34 male volunteer patients aged 35-75 years, newly
      diagnosed with CAD by conventional coronary angiography. Patients with CAD were divided into
      the "Omega-3 Group (n:16)" and "Control Group (n:18)". Low-fat diet principles were explained
      to both groups at baseline. While 1.560 mg/day omega-3 FA supplementation was given to the
      patients in the omega-3 group for eight weeks, but not in the control group. Food intake was
      recorded using six-day food records.
    

Detailed description: 
      The study was carried out on 34 male volunteer patients aged 35-75 years, newly diagnosed
      with coronary artery disease (CAD) by conventional coronary angiography. The study did not
      include the individuals who have dieted in the last six months, been taking an omega-3 FA
      and/or vitamin/mineral supplements or statin group drugs, been BMI <18.5 and ≥40 kg/m2, been
      fasting blood glucose ≥ 126 mg/dL, had a systemic disease such as Type 1 and Type 2 diabetes,
      kidney diseases, liver diseases, cancer and neurological diseases, active athletes, regular
      exercisers. Gazi University Faculty of Medicine Clinical Research Ethics Committee approved
      the study on 26 November 2020 with approval number 810. In addition, the necessary approval
      was obtained from the Turkish Medicines and Medical Devices Agency with the decision numbered
      66175679-514.11.01-E.290378. All participants gave signed informed consent and the study was
      conducted in accordance with Helsinki Declaration.

      Patients with CAD were divided into the "Omega-3 Group (n:16)" and "Control Group (n:18)" to
      evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially
      serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA
      supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3
      group, and the principles of a low-fat diet were explained. The principles of the low-fat
      diet without omega-3 FA supplementation were explained to 18 participants with CAD in the
      control group. The data of the participants were collected at the beginning, every 15 days
      and at the end of the 8th week.
    

Intervention name(s): Omega-3 fatty acid supplementation
Intervention type(s): Dietary Supplement
Intervention description(s): Patients with CAD were divided into the "Omega-3 Group (n:16)" and "Control Group (n:18)" to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Patients with CAD were divided into the "Omega-3 Group (n:16)" and "Control Group (n:18)". Low-fat diet principles were explained to both groups at baseline. While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
Masking: Single (Investigator)
Primary purpose: Treatment
Keywords: Fetuin-A; Omega-3 fatty acid; Coronary artery disease; Nutrient intake